Clinical Trials Directory

Trials / Completed

CompletedNCT06596096

Risk Factors for Beta-lactam Target Non Attainment in Critically Ill Patients BETALACTACRIT

Risk Factors for Beta-lactam Target Non Attainment in Critically Ill Patients

Status
Completed
Phase
Study type
Observational
Enrollment
300 (actual)
Sponsor
Centre Hospitalier de Saint-Brieuc · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Beta-lactams agents are time-dependent antibiotics. Their bactericidal effects are associated with the time spent above the minimal inhibitory concentration (MIC) of the bacteria. In ICU patients, many pathophysiological changes may occur, which significantly alter beta-lactam pharmacokinetics (increasing in distribution volume, hypoalbuminemia or change in glomerular filtration rate…), leading to antibiotic underexposure, which may explain some treatment failures and risk of emergence of a multi-resistant bacteria. Many guidelines advocate to reach a fixed target for the steady-state free plasma concentration of beta-lactam between 4 and 8 times of the MIC. However, clinical evidences supporting that septic patients in ICU would benefit from such optimization remain low and contradictory, and use of surrogate MICs based on critical breakpoints instead of actual MICs are significant limitations in the description of beta-lactam exposure among ICU patients with sepsis. In this study, the investigators aim to indentify profiles of intensive care unit patients which are more likely to be associated with pharmacological failure (\< 4 time the MIC of the bacteria). The investigators also aim to identify association between failure and poor clinical outcome.

Detailed description

The duration of patient participation extends from the inclusion visit (D1), to discharge from intensive care; if the participant is still in intensive care at D90, the last visit with data collection will be at D90. The maximum duration of participation in the study will therefore be 3 months. Taking into account 3 months of set-up, 1 year of recruitment, 3 months of participant follow-up, 3 months of data processing and 3 months of interpretation, 2 years will be sufficient to carry out this project.

Conditions

Timeline

Start date
2023-06-12
Primary completion
2025-06-11
Completion
2025-06-30
First posted
2024-09-19
Last updated
2025-07-09

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06596096. Inclusion in this directory is not an endorsement.